These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 21147904)

  • 21. Locally advanced cervical cancer: what is the standard of care?
    Al-Mansour Z; Verschraegen C
    Curr Opin Oncol; 2010 Sep; 22(5):503-12. PubMed ID: 20473164
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neo-adjuvant platinum-based chemotherapy followed by chemoradiation and radical surgery in locally advanced cervical cancer (Lacc) patients: A phase II study.
    Ferrandina G; Palluzzi E; Gallotta V; Gambacorta MA; Autorino R; Turco LC; Macchia G; Cosentino F; Gui B; Mattoli MV; Ronzino G; Valentini V; Scambia G
    Eur J Surg Oncol; 2018 Jul; 44(7):1062-1068. PubMed ID: 29753611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of Biologics in First-Line Treatment of Colorectal Cancer.
    Mahipal A; Grothey A
    J Oncol Pract; 2016 Dec; 12(12):1219-1228. PubMed ID: 27943689
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multimodal treatment of locally advanced cervical cancer.
    Dueñas-González A; Cetina-Pérez L; Oñate-Ocaña LF; Rivera L; Lopez-Graniel C; González-Enciso A; Candelaria M; Mohar A
    Arch Med Res; 2005; 36(2):129-35. PubMed ID: 15847945
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of angiogenesis in the treatment of non-small cell lung cancer.
    Keedy VL; Sandler AB
    Cancer Sci; 2007 Dec; 98(12):1825-30. PubMed ID: 17892508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-angiogenesis agents in metastatic or recurrent cervical cancer.
    Monk BJ; Willmott LJ; Sumner DA
    Gynecol Oncol; 2010 Feb; 116(2):181-6. PubMed ID: 19861227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Global strategies for the treatment of early-stage and advanced cervical cancer.
    Dueñas-González A; Campbell S
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):11-7. PubMed ID: 26626039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent advances and problems in primary therapy for cervical cancer in Taiwan.
    Chen CA; Hsieh CY
    J Formos Med Assoc; 2004 Jul; 103(7):511-8. PubMed ID: 15318272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
    Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vascular endothelial growth factor receptors and the therapeutic targeting of angiogenesis in cancer: where do we go from here?
    Bruce D; Tan PH
    Cell Commun Adhes; 2011 Oct; 18(5):85-103. PubMed ID: 22017472
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of vascular endothelial growth factor (VEGF) and its mRNA in uterine cervical cancers.
    Fujimoto J; Sakaguchi H; Hirose R; Ichigo S; Tamaya T
    Br J Cancer; 1999 May; 80(5-6):827-33. PubMed ID: 10360662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blocking the interaction of vascular endothelial growth factor receptors with their ligands and their effector signaling as a novel therapeutic target for cancer: time for a new look?
    Bruce D; Tan PH
    Expert Opin Investig Drugs; 2011 Oct; 20(10):1413-34. PubMed ID: 21864224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted agents in ovarian cancer.
    Kristedja TS; Morgan RJ; Cristea M
    Womens Health (Lond); 2010 Sep; 6(5):679-94. PubMed ID: 20887168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biology of vascular endothelial growth factor and its receptors in head and neck cancer: beyond angiogenesis.
    Christopoulos A; Ahn SM; Klein JD; Kim S
    Head Neck; 2011 Aug; 33(8):1220-9. PubMed ID: 21755565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. State of the science in cervical cancer: where we are today and where we need to go.
    Dizon DS; Mackay HJ; Thomas GM; Werner TL; Kohn EC; Hess D; Rose PG; Covens AL
    Cancer; 2014 Aug; 120(15):2282-8. PubMed ID: 24737608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia.
    Guidi AJ; Abu-Jawdeh G; Berse B; Jackman RW; Tognazzi K; Dvorak HF; Brown LF
    J Natl Cancer Inst; 1995 Aug; 87(16):1237-45. PubMed ID: 7563170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The issues regarding postoperative adjuvant therapy and prognostic risk factors for patients with stage I-II cervical cancer: A review.
    Takekuma M; Kasamatsu Y; Kado N; Kuji S; Tanaka A; Takahashi N; Abe M; Hirashima Y
    J Obstet Gynaecol Res; 2017 Apr; 43(4):617-626. PubMed ID: 28190285
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer.
    Cao C; Albert JM; Geng L; Ivy PS; Sandler A; Johnson DH; Lu B
    Cancer Res; 2006 Dec; 66(23):11409-15. PubMed ID: 17145887
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Angiogenesis in Colorectal Cancer: Antibodies.
    Chan E
    Cancer J; 2016; 22(3):179-81. PubMed ID: 27341595
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mathematical Modeling of Cellular Cross-Talk Between Endothelial and Tumor Cells Highlights Counterintuitive Effects of VEGF-Targeted Therapies.
    Jain H; Jackson T
    Bull Math Biol; 2018 May; 80(5):971-1016. PubMed ID: 28439752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.